O8Z Stock Chart & Stats
€2.69
€0.00(0.00%)
At close: 4:00 PM EDT
€2.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.69 - €2.96
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.57M
Enterprise Value€2.20
Total Cash (Recent Filing)€5.34M
Total Debt (Recent Filing)€739.00K
Price to Earnings (P/E)―
Beta-1.93
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding4,788,425
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.16
Price to Sales (P/S)0.18
P/FCF Ratio-0.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€20.75M
Bulls Say, Bears Say
Bulls Say
Regulatory Clearance ExpansionThe expanded 510(k) broadens Microdacyn’s approved clinical uses and packaging configurations, increasing total addressable market across acute and chronic wounds and OTC minor-skin uses. Durable regulatory clearance supports partner commercialization, raises adoption barriers for competitors, and strengthens long-term product credibility.
Revenue Growth And Margin ImprovementSustained top-line growth and expanding gross margins indicate improving product economics and operating leverage as scale increases. If repeat purchase dynamics in wound care persist, margin gains and positive adjusted EBITDA signal a move toward durable profitability once SG&A stays controlled and commercialization scales further.
Manageable LeverageRelatively low financial leverage reduces near-term solvency risk and preserves flexibility to raise capital or invest in commercial expansion. This balance sheet posture supports continued operations while the company works toward positive cash flow, and lowers the likelihood of immediate distress from modest revenue volatility.
Bears Say
Negative Cash Flow / Worsening Cash BurnSustained negative operating and free cash flow means the business consumes cash rather than self-funds growth. Worsening FCF trends increase reliance on external capital, restrict the ability to reinvest organically, and heighten execution risk if commercialization costs or working capital needs rise before consistent positive cash conversion is achieved.
Persistent Net Losses And Negative MarginsDespite revenue gains, ongoing negative operating and net margins mean the company is not yet delivering sustainable profitability. Negative margins depress returns on equity, can erode shareholder value if losses persist, and imply the need for continued scale, tighter cost control, or higher-margin product mix to turn fundamentals durable.
Reliance On Equity FinancingRegular use and expansion of at-the-market equity programs signals dependence on dilution to fund operations given negative cash flow. Ongoing equity raises can dilute existing shareholders and indicate limited internal funding capacity; structurally raises financing risk if capital markets tighten or share liquidity is constrained.
Sonoma Pharmaceuticals News
O8Z FAQ
What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was €2.69 and its highest was €2.96 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Sonoma Pharmaceuticals’s market cap is €4.57M.
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
Sonoma Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 102 days.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.078 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sonoma Pharmaceuticals overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 4,788,425 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of -€0.078 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:O8Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Technical Analysis
Perrigo Company
―
Organogenesis Holdings
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―
Journey Medical Corp
―